Stock Alert for Rite Aid Corp. (RAD)
  • Stock Alert for Rite Aid Corp. (RAD)
  • " />

    Stock Alert for Rite Aid Corp. (RAD)

    Rite Aid Corp. (RAD) is a retail drugstore chain in the United States, operating in 31 states across the country and the District of Columbia. In its stores, RAD sells prescription drugs and front end products, which include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, beverages, convenience foods, greeting cards, seasonal merchandise, and various other everyday and convenience products, as well as photo processing products. The Company sells its products under the Rite Aid brand. It offers its products to customers covered by third party payors, such as insurance companies, prescription benefit management companies, government agencies, private employers or other managed care providers. It has a strategic alliance with GNC to operate GNC stores within Rite Aid stores.  As of the fiscal year ended February 26, 2011, RAD operated 4,714 stores.

    RAD was incorporated in 1968 and is headquartered in Camp Hill, Pennsylvania.

    Share Statistics (07-Apr-11) FY












    Symbol RAD Revenue, $Mn 26.29B 25.67B -2.4% 6.35B 6.20B -2.4%
    Current price $1.08 Gross marg. 26.8% 26.6% -0.7% 26.5% 26.5% 0.0%
    52wk Range: $0.86-$1.49 Oper. margin -1.9% -1.3%
    Avg Vol (3m): 7,750,880 Net margin -11.1% -2.0% -82.0% -1.3% -1.3% 0.0%
    Market Cap. 961.46M
    Shares Outstanding 890.24M EPS, $ -1.80 -0.43 -76.1% -0.07 -0.08 14.3%

    Source:, SEC Filings.

    Investment Highlights

    Shares of RAD gained Thursday after drugstore chain released fourth-quarter figures showing a narrowed loss and an increase in its adjusted EBITDA. The Company attributed the results to fewer charges, lower overhead costs and improving same-store sales, offset by higher lease termination and impairment charges. It also cited growth of its wellness+ loyalty program, which now has more than 36 million members.  RAD’s fourth-quarter net loss of $205.7 million, or $0.24 per share, was in line with analysts’ expectations.

    Quarterly revenues came in at $6.5 billion, flat to last year’s fourth-quarter revenues of $6.5 billion.  The Company reported an increase in sales at stores open at least a year, consisting of a 1% increase in the front end and a 0.8% increase in the pharmacy. It reported that prescription sales accounted for 66.7% of total drugstore sales and third-party prescription revenue was 96.3% of pharmacy sales.

    For the current fiscal year, the Company expects to post a net loss between $370 million and $560 million, or a loss of $0.42 to $0.64 per diluted share. This is despite an expected rise in sales. RAD expects sales to be between $25.7 billion and $26.1 billion in fiscal 2012 with same stores sales expected to range from an increase of 0.5% to an increase of 2.0% over fiscal 2011.  According to the Company, its outlook fiscal 2012 is based on current same store sales trends, a challenging reimbursement rate environment and the impact of continued investments the Company plans to make in its customer loyalty program and other initiatives to grow sales. The Company expected capital expenditures to be about $300 million, which includes significantly increasing the number of store remodels and prescription file buys.

    For the fiscal year ended February 26, 2011, RAD’s stores in operation totaled 4,714. The Company opened three new stores, relocated 28 stores, remodeled 19 stores and closed 69 stores.

    RAD jumped 2.36% to close Thursday at $1.09. Approximately 18.04 million shares have traded hands during the session, versus the 10-day average volume of 6 million.  In the past 52 weeks, shares of RAD have traded between a low of $0.86 and a high of $1.49. RAD is currently below its 50-day moving average of $1.17 and above its 200-day moving average of $1.03. At Thursday’s closing market price, the market capitalization of the Company stands at $965.91 million and it has 890.24 million outstanding shares.

    Visit RAD at


    Financial Strength (07-Apr-2011) Company Industry Sector S&P 500
    Quick Ratio (MRQ) 0.49 0.67 0.63 0.67
    Current Ratio (MRQ) 1.86 1.34 0.87 0.99
    LT Debt to Equity (MRQ) 17.34 21.29 115.14
    Total Debt to Equity (MRQ) 27.65 30.63 164.59
    Interest Coverage (TTM) -3.71 2.47 0.60 16.81

    Source:, SEC Filings.

    Analyst Consensus

    This is the consensus forecast among seven polled investment analysts. Against the Rite Aid Corp company.

    Analyst Detail Buy Outperform Hold Underperform Sell No Opinion
    Latest 1 0 4 1 1 0
    4 weeks ago 1 0 5 1 1 0
    2 months ago 1 0 5 1 1 0
    3 months ago 2 0 5 1 1 0
    Last year 2 0 4 1 0 0

    The four analysts offering 12-month price targets for RAD have a median target of 1.35, with a high estimate of 4.00 and a low estimate of 1.00. The median estimate represents a 28.57% increase from the last price of 1.05.


    Consensus Estimates Analysis

    # of Estimates Mean High Low 1 Year Ago
    SALES (in millions)
    Quarter Ending May-11 3 6,373.48 6,439.41 6,324.60 6,440.75
    Quarter Ending Aug-11 3 6,142.06 6,196.49 6,111.90 6,329.95
    Year Ending Feb-11 8 25,163.70 25,312.00 25,039.00 25,466.70
    Year Ending Feb-12 8 25,132.40 25,692.00 24,857.70 25,834.00
    EARNINGS (per share)
    Quarter Ending May-11 5 -0.09 -0.08 -0.11 -0.10
    Quarter Ending Aug-11 5 -0.16 -0.13 -0.19 -0.12
    Year Ending Feb-11 8 -0.62 -0.53 -0.66 -0.52
    Year Ending Feb-12 8 -0.47 -0.39 -0.62 -0.38


    Technical Analysis


    On Wednesday, RAD closed above its 20-day moving average. This is generally considered to be an indication of a bullish trend.

    RAD is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.

    RAD’s MACD is currently indicating a weak bullish signal. Although the MACD is trending above the signal line, the indicator is still below 0, which suggests that the underlying moving averages are bearish.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    Apr07-2011 symbol Share, $ $ Mn 2011 2012 2011 2012
    CVS Caremark Corp CVS 35.47 48.53B 12.81 11.30 0.45 0.43
    Walgreen Co. WAG 41.33 37.99B 15.84 13.82 0.53 0.50
    Wal-Mart Stores Inc. WMT 53.00 185.03B 11.94 10.86 0.42 0.40
    Drug Stores Median
    Rite Aid Corp. RAD 1.08 961.46M n/a n/a 0.04 0.04

    Source: Thomson Financial

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

    Leave a Reply

    Your email address will not be published. Required fields are marked *